felt Thanks
The DCM Foundation Is Teaming up with the Children’s Cardiomyopathy Foundation to Call Attention to a Deadly Heart Disease The DCM Foundation is proud to partner with the Children’s Cardiomyopathy Foundation (CCF) to promote Children’s Cardiomyopathy Awareness Month throughout the month of September. The awareness month calls attention to the signs, symptoms, and risk factors for
Read More… from Teaming Up for Children’s Cardiomyopathy Awareness Month
The Global Heart Hub has launched a new webinar series called “Empower.” These quarterly webinars are co-hosted with patient organizations within the GHH affiliate community. The goals of this series are two-fold: 1.) To support the shared commitment to reaching and empowering the global patient community and creating a collective voice. 2.) To focus on
Read More… from Global Heart Hub’s New “Empower” Webinar Series
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced that it has completed the build-out and operational launch of its Genetic Medicines Manufacturing Center in Union City, California. Tenaya is advancing a
Renovacor Announces Partnerships with the Dilated Cardiomyopathy Foundation, the Heart Failure Society of America, and the American Association of Heart Failure Nurses to Help Increase Awareness of Genetic Heart Disorders PHILADELPHIA, PA, February 28, 2022 — Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients
Tenaya Therapeutics, a biotechnology company committed to discovering, developing, and delivering curative therapies that address the underlying causes of heart disease, is sponsoring a study to better understand pediatric cardiomyopathy due to the MYBPC3 mutation. The MyClimb Natural History Study is designed to collect and evaluate information on the course of cardiomyopathy in children and adolescents <18
Read More… from Natural History Study Seeks Participants with MYBPC3 Genetic Mutation
By creating scientific forums to foster collaboration and creativity, Tenaya Therapeutics has been able to optimize gene therapy manufacturing. Such advancements can help make gene therapy more accessible and affordable for larger patient populations. Read the full article here: https://www.cellandgenecollaborative.com/doc/the-ties-that-bind-engineering-a-cgt-manufacturing-centric-culture-0001
The following documentary film demonstrates the discovery of the BAG 3 genetic mutation that can cause DCM and the development of the gene therapy that became Renovacor. Please click here to view the video to learn more: https://vimeo.com/173290791
Read More… from BAG3 Mutation Discovery & Gene Therapy Development
We’d like to say thank you to Dr. James Priest for being our guest presenter on this month’s DCM Foundation webinar, “The Science Behind DCM Gene Therapies – and Tenaya’s Quest to make it Affordable for All”. Dr. Priest is a pediatric cardiologist and the Senior Director of Cardiovascular Genetics at Tenaya Therapeutics. As he
Read More… from Thank you to Dr. James Priest from Tenaya Therapeutics
